Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$29 Mln
P/E Ratio
--
P/B Ratio
53.83
Industry P/E
--
Debt to Equity
-0.4
ROE
-10.16 %
ROCE
212.26 %
Div. Yield
0 %
Book Value
--
EPS
-1.52
CFO
$-672.00 Mln
EBITDA
$-1,430.64 Mln
Net Profit
$-1,556.34 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
FibroGen (FGEN)
| -40.04 | 0.79 | -37.00 | -72.15 | -68.60 | -61.58 | -35.74 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
FibroGen (FGEN)
| -39.99 | -94.47 | 13.62 | -61.98 | -13.52 | -7.32 | -2.35 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl... hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 350 Bay Street, San Francisco, CA, United States, 94133 Read more
CEO & Director
Mr. Thane Wettig
CEO & Director
Mr. Thane Wettig
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of FibroGen Inc (FGEN) stood at $ 215 Mln as on 31-Dec-24
The share price of FibroGen Inc (FGEN) is $0.32 (NASDAQ) as of 23-Apr-2025 14:39 EDT. FibroGen Inc (FGEN) has given a return of -68.6% in the last 3 years.
FibroGen Inc (FGEN) has a market capitalisation of $ 29 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of FibroGen Inc (FGEN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the FibroGen Inc (FGEN) and enter the required number of quantities and click on buy to purchase the shares of FibroGen Inc (FGEN).
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 350 Bay Street, San Francisco, CA, United States, 94133
The CEO & director of Mr. Thane Wettig. is FibroGen Inc (FGEN), and CFO & Sr. VP is Mr. Thane Wettig.
There is no promoter pledging in FibroGen Inc (FGEN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| FibroGen Inc (FGEN) | Ratios |
|---|---|
|
Return on equity(%)
|
78.96
|
|
Operating margin(%)
|
-489.92
|
|
Net Margin(%)
|
-516.86
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of FibroGen Inc (FGEN) was $0 Mln.
$0.02
(
